BACKGROUND AND INTRODUCTION
While it would be impossible to envision the practice of radiation oncology in 2013 without computers, it is noteworthy that current computing infrastructures in radiation therapy are largely based around 1980s "single workstation" models. In these models individual software applications such as treatment planning systems (TPSs) and treatment management systems (TMSs) are typically connected via data transfers over a network, importing and exporting data from modules such as imaging devices, treatment machines, and ancillary software systems. Consolidated data flow from simulation to treatment is available for clinics that adopt a "single vendor" approach, yet even these installations have largely grown out of combinations of existing single-purpose applications.
Recent years have seen the proliferation of server-based "virtual machines" that facilitate remote user access and leverage centralized computations while minimizing large data transfers over network. There have been some advances in making use of more parallel computing environments, including distributed calculation frameworks for dose calculation and enterprise software systems. However, like the conjoining of a TPS and TMS, these advances are largely accomplished by taking existing single workstation applications and transplanting them onto a server-based platform. This evolution is understandable given the needs of commercial development and the regulatory oversight of medical software. However, from the perspective of clinical users, it must be asked whether current computing infrastructures are ideal for the task of modern clinical radiotherapy.
The fundamental question that guides this Vision 20/20 paper is: If radiotherapy computing systems were designed from scratch in 2013, what would they look like? We seek to identify trends in advanced computing that will shape clinical radiation oncology in the coming years and consider how an ideal computing environment could enhance patient care. A survey of the broader literature 1-10 and radiotherapy research [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] suggest that the following developments hold promise to improve clinical radiation oncology computing:
r Cloud-based service models r Aggregate data analyses r Parallel computation r Automation That no comprehensive clinical infrastructure yet exists designed to make use of these technologies leaves an opening for a new paradigm in radiotherapy computing systems. The goal of any next-generation radiotherapy information system would be (a) an improvement in what current systems already do and (b) an expansion to new clinical applications not currently in practice. This Vision 20/20 paper attempts to describe the general themes of a next-generation computational infrastructure and what impact its adoption might have on maximizing efficiency, quality, and safety in clinical radiation oncology.
CLOUD COMPUTING IN CLINICAL RADIATION ONCOLOGY
As outlined in a recently published Vision 20/20 paper regarding the use of cloud computing for medical imaging, 4 cloud-based infrastructures are poised to play an increasingly important role in medical software applications. Loosely defined by the National Institute of Standards and Technology, 6 cloud computing is "a model for enabling ubiquitous, convenient, on-demand network access to a shared pool of configurable computing resources (e.g., networks, servers, storage, applications, and services) that can be rapidly provisioned and released with minimal management effort or service provider interaction." Known more familiarly through widely used web-based software as a service (SaaS) applications such as Google's Gmail, cloud computing manifestations have yet to penetrate fully to standard clinical radiation oncology software applications such as TMS and TPS. The transition to such "on-demand network access" is underway, as evidenced by several prominent TMS and TPS vendors making their applications available through server-based thin-client applications or network-based virtual client (e.g., Citrix R ) interactions with users. Depending upon the interpretation of the somewhat ambiguous terms that comprise the current connotation of cloud computing, such clinical systems already comprise a local, i.e., single-clinic level, cloud-based platform as a service (PaaS).
While these developments can facilitate the ubiquitous access to clinical software applications that is promised by cloud computing, the full realization of a cloud-based clinical informatics system awaits a time when the computational hardware platform, network servicing, data storage, and software administration have all broken away from the level of hospital management and transferred to an extra-institutional provider. This would be roughly analogous to moving from a locally managed email server to Google's Gmail, a transition that rightfully prompts the question as to whether such a transition would be desirable in the first place. Unlike the subsequent section regarding the clear advantages of increased computational speed through parallel processing, the benefits of moving clinical software applications to the cloud is not immediately obvious, nor is the transition certain.
For the purposes of this study, the key definitional concepts for a cloud-based radiotherapy informatics system include:
r Off-site storage of clinical radiotherapy data, e.g., imaging, treatment planning data, etc.
r SaaS modules for clinical radiotherapy applications, e.g., TMS and/or TPS r Protected health information (PHI) and clinical data access controlled by the local institution r Multiple institutions housing data on a single platform The latter item distinguishes cloud-based systems from locally managed networked software applications, i.e., an entity other than the individual institution is responsible for managing the data storage, software delivery, and computational resources. This system would be most advantageous if multiple institutions utilized the PaaS, with the provider-be they vendor, multi-institutional consortium, or otherwise-scaling computational resources based on local demands. This system should not be a goal unto itself; the move to fully cloudbased platforms should be pursued to advance clinical goals and improve patient care. However, it is possible that this will one day be adopted to save costs at individual institutions by eliminating the need for local IT resources. Subsequent sections will touch on the clinical applications and safety concerns of operating clinical software on the cloud.
Even with the uncertainty of how, when, or even if the transition to a fully cloud-based clinical radiotherapy platform will occur, it is possible that this transition would ultimately be accomplished with few disruptions. TMSs are already designed to operate in a distributed fashion, taking data imports from imaging devices and caching radiotherapy treatment machine programming instructions to, for example, linear accelerator control computers that return information to the server after a completed patient treatment. Core applications such as treatment planning become but part of the SaaS systems on the cloud, with the planner interacting through a networked application from whatever workstation or wireless device is at hand. The delivery of radiotherapy software applications to handheld devices such as mobile phones or handheld tablets is already possible using existing networked applications. 26, 27 As this would be a primary goal of moving to cloud-based infrastructures, such ubiquitous access to clinical applications would become commonplace.
AGGREGATE DATA ANALYSES AND NEW CLINICAL APPLICATIONS
Aggregate data analysis can be generally defined as the synthesis of quantitative information from a multiplicity of measurements. In the case of radiotherapy, this could take the form of computing some summary statistic of interest across multiple patients, multiple treatment plans, multiple treatment fractions, multiple treatment devices, etc. Aggregate data analysis is hardly a new advance; indeed, it forms the basis of clinical trials and nearly every clinical research project published in the literature. However, it is readily distinguished from the single-patient focus of clinical radiotherapy where, for example, individual dose volume statistics are computed for a candidate treatment plan. The reason that aggregate data analysis is mentioned in this context of next-generation computing infrastructures comes from the recognition that investigations over multiple patients and institutions are conducted almost entirely in the context of research and not as a core clinical function. By design, current clinical radiotherapy computational infrastructures aim to take an individual patient from simulation through the end of treatment, successively transferring and incorporating data from one application to the next. While this is not a deficiency for ongoing clinical management, quality improvement investigations are hindered by the fact that clinical data repositories are not designed to facilitate multipatient retrospective data analyses. Several institutions have designed platforms that analyze the TPSs (Refs. 21, 23, and 24) or TMSs (Ref. 27) databases to good effect, yet in an age of "Big Data" analyses 1, 5 it should not be a cottage industry to conduct quality improvement studies that have been advocated for decades in radiotherapy 28 and are mandated for maintenance of professional certification. 29 Variations in local software usage and data management will inevitably stymie some multi-institutional analyses, but clinic-level quality investigations are still incredibly valuable. If clinical practice becomes more standardized in the use of common cloud-based informatics systems, both individual and multi-institutional studies will become more meaningful.
As outlined in the aforementioned Vision 20/20 paper, 4 cloud computing offers scientific endeavors new avenues for parallel computations across large data sets. Insofar as many medical research applications are functionally identical to clinical quality improvement studies, the value of cloud-based computing infrastructures has immediate applications in clinical radiotherapy. Whether a clinical TMS is fully replaced by a cloud-based infrastructure or an ancillary repository that runs aside an existing TMS, an ideal cloud-based system should be designed to give clinicians the ability to construct system-level queries that can enlighten users on normative clinical practice.
As an example, consider a clinician that wants to know whether intensity-modulated radiotherapy (IMRT) differs from volumetric-modulated arc therapy (VMAT) 
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For clinicians without sufficient background in programming to write such queries, graphical user interfaces could build around simple search platforms, though some versatility would likely be lost in the process. It is important to emphasize that the above query would not be a research investigation into whether VMAT or IMRT delivers better treatments, but a clinical investigation into the local comparative practice of these techniques. Currently, this simply expressed query would involve either advanced-level programming knowledge of the TPS and/or TMS databases or, worse yet, a manual patient-by-patient extraction of the data. Beyond the undeniable tediousness of such manual inquiry, the stated investigation does not even involve any data transfer. It is easy to envision an investigation that would necessitate the transfer of sizeable imaging data, especially in the era of IGRT where fractionated courses of therapy can generate a multitude of secondary image studies beyond the imaging acquired before prospective treatment planning. For example, the following query seeks to quantify, based on cone-beam CT (CBCT) imaging, how frequently the prostate is found to be outside of the PTV margins: 
Much is presumed in the above query, including the presence of a validated command line autosegmentation routine that can accurately propagate prostate contours from one image to another. Obviously several incarnations of autosegmentation software already exist, but to use them for this clinical question one would need to extract the planning CT and every CBCT from every prostate patient, then manually propagate contours one-by-one. The ability to connect plug-in service modules, such as autosegmentation, to data queries is therefore a prerequisite for a sufficiently complex radiotherapy analytics system. Such queries are hardly restricted to treatment planning investigations. Any clinical information system with a collection of longitudinal data is amenable to an aggregate survey. An example of a completely different type of investigation is shown below, whereby a linear accelerator machine log is queried to determine how many total monitor units of each beam energy in a given year: 
In this example, the search is conducted over data classified as "shared" by a multiplicity of institutions storing clinical data on a cloud-based radiotherapy informatics platform. Such a query would represent an important advance for the field facilitated by multiple institutions pooling data on the same cloud-based platform. As we will outline in Sec. 5, the concerns regarding data security are significant and the data that are tagged as "shared" will undoubtedly be chosen with care. Insofar as V75 in rectum portends patient outcome, 31 it may be desired by individual institutions to withhold DVH information as "local only" access along with patient PHI. There is still significant value in interinstitutional comparisons of, e.g., total monitor units used in prostate treatments, and these data elements would be less controversial to be shared across multi-institutional data pools. While understandable, the reticence to share clinical data (including outcomes information) would be a significantly missed opportunity. Interinstitutional benchmarking and transparent quality control initiatives could and should play an increasing role in health care as comparative effectiveness becomes an expected aspect of clinical practice. 32, 33 That a multi-institutional distributed radiotherapy platform could significantly lower the bar for both local and interinstitutional aggregate data analyses is, in the authors' view, a very compelling reason to advance such a clinical radiation oncology informatics system.
Machine learning is very mature subspecialty in computer science and has already been applied in some research investigations toward radiotherapy applications. 34, 35 Machine learning can be considered a specific type of aggregate analysis designed to discover correlations in multivariate data and make predictions based on those correlations. These techniques will inevitably be an important analytic tool for both clinical and research questions on large-scale clinical databases. The results of such studies will form the core of both quality control methods (comparing measured to expected values) and software that automates current manual processes, a topic that will be discussed in detail in Sec. 5.
PARALLEL COMPUTATION
One of the major advances that is certain to achieve widespread adoption in clinical radiotherapy is the use of parallel computing methods to speed up routine computational tasks. Image reconstruction, 4, 36, 37 autosegmentation, 38, 39 dose calculation, 16, 39, 40 plan optimization 19 -these tasks are all amenable to parallelization and, needless to say, the time lags in these processes serve no purpose. In this section parallel computing platforms such as grids, clusters, High Performance Computing (HPC), Graphics Processing Unit (GPU) programming, and the marriage of parallel computation to cloud services are analyzed.
Digital medical image processing has rapidly increased the computational demands as data now involve finer detail. Furthermore, the trend in recent research is to move toward highly realistic images using combined information from multimodal systems. In order to overcome these computational demands, the parallel computing concept has been introduced in the field in terms of local CPU clusters (small-medium) and grids. Monte Carlo (MC) simulations provide a ground truth tool for many medical imaging applications such as SPECT, PET, and CT, and also in radiotherapy/dosimetry, treatment planning, and quality assurance. 41 They involve critical CPU-intensive computations and most of the work corresponds to numerical calculations related to particle transportation. 42 Realistic simulations often take several days for acquisition completion in single-CPU computers. There are many studies in the literature reporting on the parallelization of MC calculations for several codes MCNP, 43 GATE, 42 SimSET, 44, 45 and SIMIND (Ref. 46 ) with a speed increase factor varying according to the number of incorporated CPUs. Moreover, several platforms have been used for such an approach like MPI, 47 openPBS, 48 Xgrid, 48 and Condor. 49 Nevertheless, clinical practice requires management of large medical image datasets for processing (reconstruction, registration, quantitative analysis), and for specialized dosimetry calculations using patients' anatomical data. Thus, small clusters could not meet all these requirements. With tens of MegaBytes for an MRI dataset to hundreds of MegaBytes for a multiresolution spiral CT-scan, the annual production of a single radiology department is estimated to be tens of TeraBytes per year. 50 Data and computing grids are an opportunity to handle and process all these volumetric data as well as transfer experimental research to clinical practice. Grids provide an infrastructure allowing multiple user communities to access and manipulate medical data. Moreover, grids offer the computing power needed to validate algorithms on large datasets and to process complete databases for applications requiring statistical information such as epidemiology. AGIR (Grid Analysis of Radiological Data) is a project started in 2004 providing medical services such as (a) interactivity and volume reconstruction, (b) online compression and cardiac image segmentation, (c) workflow management and evaluation of registration algorithms, and (d) medical data management and humanitarian medicine. 50 Grid technologies have gone further for MC applications. Recently the European Grid Infrastructure (EGI) (Ref. 51 ) and Open-Science Grid 52 have been extensively used for exploiting parallelized MC simulation for imaging, dosimetry, and radiotherapy applications. 53, 54 The parallel distribution philosophy on processing medical data in clinical routine has given rise to the use of High Performance Computing (HPC) centers. There are several HPC centers around the world which provide their infrastructure for medical services as well as for research in medicine. [55] [56] [57] GPUs, originally designed for accelerating the production of computer graphics, have emerged as a versatile platform for running massively parallel computation. Graphics hardware presents clear advantages for processing the type of datasets encountered in medical physics: high memory bandwidth, high computation throughput, and programming interfaces accessible to every nonexpert user. 20 In medicine, the ability to perform a general-purpose computation on the GPU was initially demonstrated by a group at SGI in 1994. 58 Over the years, the GPU has evolved from a highly specialized pixel processor to a versatile and highly programmable architecture performing a wide range of parallel operations. 11, 20 Medical physics applications that use GPU technologies have increased rapidly, focusing on algorithmic calculations that need high computational efficiency. Image reconstruction, registration, and segmentation are some of the most widely used processing tools that make use of Compute Unified Device Architecture (CUDA) programming. Dose calculation and treatment plan optimization speeds are also increased in the field of graphical parallel programming. Furthermore, many research groups have been interested in using GPU for visualizing medical datasets in real-time, exploiting the inherent graphics abilities of the GPU. Various codes have been written to render several datasets, including digitally reconstructed radiographs, cardiac CT scans, co-registered multimodal cardiac studies, CT-based virtual colonoscopy, and sinus virtual endoscopy. GPU computing techniques have also been developed to aid surgical planning. More recently, MC simulations are converting their code to CUDA in order to profit from the GPU parallelization. GATE, which is a widely used MC toolkit based on Geant4, has already been implemented in some parts in order to run in hybrid systems using both GPU/CPU. 12 Many dosimetric studies using MC simulations have also been reported in the literature for proton therapy, 17 calculation of gamma index, 13 and dose calculations in radiotherapy. [14] [15] [16] The combination of GPU hardware and cloud distributions is in its infancy but is seen as a likely development in clinical software deployment because, in addition to remote services, it promises scalable applications and efficient computational acceleration. According to Philbin et al. 59 PACS, as a cloud service, would demand sufficiently high network bandwidth between the radiologist's client workstation and the relevant cloud service such that two or more screens of full-resolution images are presented in less than 2 s and manipulated in real time. More recently a GPU-based rendering in a cloud computing environment was reported using the MapReduce 22 algorithm in Parsonson et al. 8 Several vendors already support GPU distribution on cloud system. 7 With some uncertainty as to implementation but none in regards to the inevitable time reductions for computational tasks which currently bottleneck clinical workflow, the day is envisioned where parallel computation makes data transfer speed the rate-limiting step in clinical radiotherapy computing. Within the current paradigm of single prospective plans for most radiotherapy patients, near-instantaneous dose calculations and plan optimizations would fundamentally alter the treatment planning process for dosimetrists, physicists, and physicians alike, all to the patient's benefit.
AUTOMATION IN CLINICAL RADIATION ONCOLOGY
The sophistication and technical complexity of radiation therapy has evolved to the point where this field is more computerized than almost any other area of medicine. There are at least 11 distinct software functionalities in a typical radiation therapy clinic, implemented either as standalone applications or the combination of multiple functionalities in a single application. These include (1) Electronic Medical Record, (2) Treatment Management Software, (3) Workflow/Enterprise Management Software, (4) Imaging System Software, (5) Treatment Planning Systems and Ancillary Software, (6) Delivery Systems Software, (7) Quality Assurance (QA) and Quality Control (QC) Software, (8) Record (procedures, QA, etc.) Management Software, (9) Outcome Databases and Related Analysis Software, (10) Archiving (PACS, etc.) Systems, and (11) Software Interface Systems. Through multiple efforts for standardization of communication formats (HL-7, DICOM, DICOM-RT, IHE-RO, etc.), database formats, and even some clinical practice standardization, 60 the interconnectivity between all these systems is no longer really a technical limitation but rather an issue of practical implementation.
If these systems can be interconnected, the question turns to how can they be improved and organized to provide a greater degree of automation in a clinical setting. We would ideally like to automate patient services (processing of patient data and care coordination) and individual practitioner (physician, dosimetrist, therapist, etc.) tasks. To decide which tasks to automate, the automation itself needs to be understood. Computerized automation has been around for five decades and in many industries it has shown that its interconnected benefits can be felt in cost reduction, productivity gains, availability, reliability, and performance. A brief examination of each of these potential benefits of automation in RT is in order.
r Cost reduction-The two major cost factors in RT are equipment and labor costs. The more automated operations are almost certain to increase the equipment costs. On the other hand, the majority of RT operations are single treatment machine facilities with small teams of people, and automation in that context is unlikely to reduce the staffing levels and labor costs. For example, a single dosimetrist may be more efficient through automation but ultimately that position is still needed even if it is not fully utilized at the same capacity. Larger clinical operations or situations where multiple clinics are networked in one system can indeed result in cost savings through increased productivity and reduced labor costs. Ultimately, to realize cost reduction and benefits of increased productivity through automation, above average patient volumes or the ability to outsource tasks are needed.
r Productivity-The initial impression about productivity through automation is that automation would lead to ability to perform conventional tasks faster and, therefore, more tasks could be completed in a typical work day. An often overlooked aspect is that the automation allows performance of tasks which traditionally could not have been performed through manual means. For example, automation may allow data mining of patient and clinical operation data and analysis and use of this data on a level that is impossible through manual means, enabling typical RT facilities to enhance services or offer new ones.
r Availability-Health care, including RT, is a service business where we provide services to patients. The level of any service and patient satisfaction can be significantly improved when the materials needed to provide a service are available in a timely manner. The timely availability of information and data typically reduces operational variability and therefore has a significant potential to improve the quality of patient services.
r Reliability-The potential improvements in reliability and robustness of RT tasks through automation are yet to be fully grasped. However, it is clear that the majority of traditional tasks in a RT facility-simulation and treatment plan ordering, data communication, contouring, treatment planning, QA/QC, system and individual patient monitoring, etc.-can be to a large extent, if not fully, automated. Automation of any of these tasks has a potential to improve reliability in performance of those activities and ultimately the quality and safety of patient treatments through reduced variability. Therefore, tasks with a high propensity for variability (e.g., treatment planning 61, 62 ) or repetitive tasks with critical importance (e.g., physics chart checks 63 ) are excellent candidates for automation.
r Performance-Most importantly, automation may allow RT facilities to operate at a far superior level where we can provide patients lower cost, higher quality, safer, and better informed treatments in a faster and more predictable manner. Again, the level to which this is achieved depends on what tasks are ultimately able to be automated.
The implementation of automation in a clinical setting can be aimed toward obvious improvements that have long been needed, these include automatic image registration, treatment planning, plan evaluation, automation of QA and QC tasks, etc. Depending on the specific task and implementation of the application, the automation of long standing practices is perhaps just a natural evolution and not a revolutionary transformation. The reason for this is that automation of tasks which have been historically performed manually can frequently just prolong antiquated practices. This does not mean that the automation of conventional tasks and workflows is not a worthy and important activity, however, this should not become the only focus and fundamental examination of our clinical practices and reconsideration in a light of modern capabilities may on many levels be much more rewarding.
A good example of automation of the traditional processes where a fundamentally different approach may evolve is treatment planning. Currently, treatment planning is a very time consuming task with great output variability. 61, 62, 64 It has been shown that it is possible to almost fully automate and/or accelerate this functionality where plans are created much faster and with greater consistency and quality. [64] [65] [66] It is instructive to consider that much of the research investigations that have made progress in automating treatment planning applications have made use of machine learning techniques applied to aggregate data, as noted in Sec. 3. Analyses on prior aggregate data that then form the core predictions for new QC checks or directly automated routines will be powerful tools for efficiency gains and quality improvement.
We could adopt thinking that if we stop with automated treatment planning, we would improve speed and quality of plans with a probable reduction in labor costs. Alternatively, we could look and say if planning can be done so quickly whether we need conventional approaches to treatment planning at all. It might be possible to eliminate dosimetry rooms entirely and distribute contouring, planning, and data management activities to imaging devices, portable devices and cloud computing, and treatment machines. Even with 20/20 vision it is difficult to forecast if this scenario will actually happen but it is safe to say that the eventual state of treatment planning will evolve much closer to the above described implementation than to the conventional practices of today. Does this mean that treatment planners would no longer be needed in RT operations, with dosimetrist positions eliminated just as block cutting positions were with the advent of multileaf collimators? The answer is most likely that they will still be needed, perhaps even more than before. If we can increase our ability to plan faster and more frequently as promised by the adaptive radiotherapy concept, these positions may be used for dose aggregation, analysis, individualized care, and many other activities which were not possible with conventional clinical practices.
Drawing on the above example, it can be envisioned that we may maintain many of our core practices but that they would be performed in a quite different manner with a much larger focus on data, quality, outcomes, and value of services that we provide. While it may seem that the RT has technologically somewhat reached a plateau, the automation promises technological and treatment advances that rival anything we have accomplished in the past.
A challenge for medical physicists will be to adapt quality and safety programs to a new era of clinical automation. It will inevitably be difficult to design end-to-end tests when multiple automated systems interact to generate, adapt, and themselves QA a patient's course of treatment. It is far too early, even in a speculative document such as this, to project how to build a quality management program around technology that has yet to be designed, let alone implemented. It is not, however, too early for clinical physicists to begin thinking about QA of the automated systems that do exist 67, 68 and to exercise considerable care as new software systems are brought into clinical practice. The Failure Modes and Effects Analysis (FMEA) methodology advocated by the forthcoming Task Group 100 report will likely become a valuable guidance document in adapting QA tasks to yet-to-be-designed automation systems. Further, given the scope of how deeply automation is likely to penetrate into the clinical radiotherapy process, it is quite possible that the safety of automated systems will be best ensured by further redundant automated systems.
DATA SAFETY CONCERNS
As with any large pooling of personal data, there are several public concerns around how data are used and protected. Recent media reports of hacking and governmental agencies monitoring online activities only heighten these concerns, especially given the very sensitive nature of medical information. The vision of using large amounts of clinical data to improve care will undoubtedly be successful, but will be restricted by the many regulatory concerns if patient confidentiality is not preserved. This is further complicated by the varying institutional policies as well as the worldwide variations in regulations around patient privacy and data use.
Clinical data are longitudinal by nature so it is crucial that they can be collected at several time points throughout a patient's life. For this reason, data must be able to be linked back to the patient regardless of what institution they were treated at or followed up in. This translates to the need of being able to uniquely identify any patient in order to add additional information to the system. Accessing and analyzing clinical data must have a purpose. In today's environment Institutional Review Boards serve as gatekeepers to insure patient awareness and access to data is reasonable and warranted to support the research activities. For clinical quality purposes the regulations are different from research activities, as physicians can collect and analyze data on their own patients to measure attributes of care. Institutions have adopted policies around what data can and cannot be used for both research and quality purposes.
In designing systems, it is crucial that both patient privacy and institutional policies are adhered to. As an example of such a design, the Oncospace model 27 developed at Johns Hopkins is a federated database model where each institution would house their own database with a common data schema and have control over their local access. Individuals within the institution would have access rights based on their need for quality and research activities governed by IRB concerns. For example, a user could be required to preface each query by selecting either "quality improvement" or "research" as the justification for an aggregate analysis. If the query is tagged as a research investigation, the user would be required to enter a valid identifier for an IRB-approved study. It would even be possible to limit data access according to the scope of the IRB-approved study, e.g., over a restricted date range or within a particular disease site.
Multi-institutional access to the federated databases is governed by institutional data sharing policies, and controlled via access only through a restricted interface for analysis. For example, policies may restrict one institution from comparing their patient outcome results directly to another institution. However, it may be possible to benchmark local outcome results across several institutions that are similar without violating an institutional policy. This level of analysis can be controlled via specific tools constructed for data sharing to comply with participating groups. More detailed analysis that may breach the broader policies would still be possible but may require additional institutional approvals.
Patient privacy in the Oncospace model is handled by storing a separate data table that has restricted access that holds all the private health information. Without access to this table, the database is anonymous, including encounter dates. Incoming data would contain PHI and internally the system can link new data to the correct patient, but once imported, it would be protected. Such a model goes a long way to protecting patient privacy from security breaches, as the hostile entity would need to penetrate two systems to gain illegitimate access to PHI.
The federated model may work with larger participating institutions that have the capacity to manage their own databases, but smaller clinics may not have that ability. The National Radiation Oncology Registry (NROR) 32, 33 poses another example that seeks broad participation across radiation oncology. The NROR model consists of a central data collection repository where PHI is included. Participating institutions have the rights to manage the data on their own patients within the system and are not able to access any information on patients outside of their institution. It is essentially an extension of the institution's data cloud and governed by a Business Associates arrangement between the NROR and the participating institution.
For analysis of the NROR data, a "limited" data set is transferred from the data collection repository to the registry database where all analysis is performed. The extent of the limited data set is governed by agreed cross institutional policies through participation agreements and through federal US regulations such as HIPAA on limited data. Analysis in the registry database is controlled by access/analysis tools and governed by the agreed to policies for participation.
These two examples highlight various ways of protecting patient privacy and adhering to regulations and policy. It is critical that all systems that house patient data are designed with these protections. In addition to data storage and access, data transfer must also be secure, i.e., with encryption protocols such as Secure File Transfer Protocol (SFTP) and Hypertext Transfer Protocol Secure (HTTPS).
Ultimately, the goal is to use data for not only research and quality purposes, but for decision support and clinical automation. If data are to be used clinically, then quality of the data is of the utmost importance. Controlled clinical trials have extensive processes to insure data quality. Some of these tools could be adopted in clinical practice, but the time pressure on clinicians to treat more patients with fewer resources renders it challenging. For this reason it is important to have tools for efficient data collection on patients that can be both used in the clinical setting and have robust quality controls.
Data quality checks can range from simple (checking for errant entry) to the more complex (alerts when data violates a multifactorial set of information criteria). A simple example is that of spelling versus grammar checking in text. The spell check is simply testing against a dictionary of single terms, whereas the grammar checking is looking at how multiple types of words are put together with punctuation and alerting the user of the quality errors. This same concept could be applied to clinical systems as a model of improving data quality and alerting to patient safety concerns. Such systems can be governed by known algorithms for data integrity and be augmented by identifying data that differs from the norm of similar patients.
The inverse of the using these checks to insure data quality is to use the same quality checks to alert clinicians on patient safety concerns. One example of this is in e-prescribing medications and the systems that alert clinicians to potential adverse drug-drug interactions. This concept can be applied to insure safety in radiotherapy where clinicians are alerted when uncommon prescriptions are used for a particular diagnosis, or when volumes or doses are out of normal range for a particular patient. Such safety checks represent a leveraging of the aggregate analysis capabilities of such advanced computing systems, providing yet another example of how these concepts enhance patient safety efforts by expanding quality checks in ways that would be impractical to be accomplished manually.
One further issue regarding data security involves the fact that that a health care provider does not own a patient's clinical data but are, instead, custodians of a patient's medical information. According to HIPAA, the patient has a right to obtain copies of their medical record, meaning that as custodians of the information a provider is obliged to make these data available. Thus, for the purposes of patient access to their EMR or issues involving legal discovery, the cloud provider will be minimally required to make possible the efficient transfer of data from provider to patient as well as ensuring that the data is not deleted or otherwise inaccessible. 69 Normal requests for data should come through clinical users and not directly from patients to the cloud provider. While the precise nature of the contractual agreements between cloud providers and clinical users is yet to be determined, it is likely that should cloud providers be directly requisitioned for information they will either be unable to do comply due to (a) PHI encoded information being withheld from providers by local clinical users (as described earlier in this section) and/or (b) contractual restrictions on direct servicing of data requests.
IMPROVING RADIOTHERAPY THROUGH ADVANCED CLINICAL INFORMATICS
A full flourishing of all of the elements described thus far will undoubtedly take some time to penetrate to common usage. It has been taken somewhat as a given that the implementation of these advanced technologies would be a positive development; it is the aim of this section to demonstrate that this would be the case and what the practice of radiation oncology might look like in the not-too-distant future.
7.A. Quality and safety improvements
As noted in Secs. 2 and 5, integrating imaging, delivery, and clinical data into a distributed, federated database designed for system-wide analyses will significantly lower the bar for quality improvement studies, hopefully making them commonplace endeavors.
For patient-level quality control and quality assurance, building safety checks based not only on pattern-finding in local experience but also broader multi-institutional efforts could allow for much more sensitive outlier detection. Indeed, such an endeavor is already underway in the "Plan Veto" through the IHE-RO initiative 70 with the goal of preventing such catastrophic accidents like the fatal incident in New York where a head-and-neck patient was subjected to open fields that delivered the monitor units designed for an IMRT plan. 71 For device-level quality assurance, multi-institutional sharing of, e.g., linear accelerator measurement data using standardized acquisition equipment could put individual linear accelerator beam performance in the context of hundreds, perhaps even thousands, of identical devices. While manufacturers maintain such databases based on local service engineer reports, to date no regimented system of cross-validation exists for the core beam data upon which all of our linear accelerator beam models rely.
For institution-level quality management programs, computer-aided quality improvement investigations on both local and multi-institutional data pools can inform Risk Priority Number (RPN) scoring in FMEA analyses 72 not only by estimates from clinicians but also by multi-institutional error reporting databases comprised of actual event logs from a potentially huge pool of clinical sites. The idea of a national reporting infrastructure has been considered, 73, 74 and while the systematic practice of error reporting is an end unto itself the endeavor will only realize its full potential when this data can be queried by end-users to advance local quality initiatives. Further, the integration of local clinical and device data in a single database will significantly lower the bar for maintenance of "smart" systems that control operations in real time. As new quality control routines are developed based on evolving quality improvement initiatives, daily dashboards and local "red flag" signals can allow for much more sensitive and responsive operations than the current weekly chart check paradigm.
7.B. Efficiency improvements
Operating a modern radiotherapy clinic that treats several hundred patients per day will require ever more elements of computer-aided efficiency to maintain optimal treatments. Section 5 already discussed the intuitive efficiency gains from automation, and a union of a cloud-based informatics system with automated analysis plug-in modules should increase efficiency not just for discrete workflow tasks such as treatment planning but for system management applications and alerting that bring the data to the user Next generation systems would be the framework and vehicle for specific clinical improvement modules (e.g., administration dashboards, remote device focused user interactions, etc.).
7.C. Adaptive radiotherapy
Adaptive radiotherapy 75, 76 has been one of the most active areas of research in medical physics for well over a decade, and the largest impediments to clinical implementation of ART-data management and workflow, automation, and computational demands-are directly addressed through the advancement of the technologies considered in this Vision 20/20 paper. Workflow improvements through faster on-board image processing, automated plan adaptation, and QA/QC analysis routines directly facilitate the processes necessary for ART, and advanced informatics could efficiently conduct studies into its clinical benefit. QA and safety considerations for ART could be addressed through automatic secondary dose calculations and machine-level implementation of the Plan Veto concept. It is expected that for ART to become commonplace, some if not all of the concepts outlined in this Vision 20/20 paper will have to be realized as well.
7.D. Improvement in outcomes analyses and clinical effectiveness
Current practice of radiation therapy is driven by outcomes data. Local outcomes data are typically collected using inhouse databases that can be as simple as a spreadsheet, with planning data and outcomes data being kept separately. This necessitates at least one intermediate step, for example, exporting Dose Volume Histograms (DVH) for every patient from the planning system, before dose-volume-response analyses commences. This also precludes a "push of a button" check for reasons for any observed adverse effects. A significant hope of advanced clinical informatics systems would be the potential to learn ever more about the safety and effectiveness of the therapies we provide. The rapid adoption of technological advancements in radiotherapy has made outcomes analyses of both treatment regimens and the systems that deliver them to be separated substantially in time. For example, published literature demonstrating the superiority of IMRT for the treatment of prostate 77 and head-and-neck 78 appeared more than 10 years after this delivery modality entered widespread use, and similar studies demonstrating the benefits of IGRT (Ref. 79) show a similar time lag. Clinical implementation is typically based on planning studies.
These studies, while valuable, often have a clause that while differences between the reference and novel method to deliver dose are statistically significant, this may not translate to improved outcomes. Ultimately, technological advances have to be evaluated using quantifiable measures. These measures can be separated from outcomes by quantifying, for example, patient throughput or MU per fraction. However, the ultimate measure of success is improvement in outcomes which can manifest as decreased toxicity or increased tumor control. Currently, used patient management systems do allow recording medical history and outcomes, but this capability remains largely unused in favor of in-house software.
As described in Sec. 5, quality assurance of the data is a requisite task despite the substantial time and effort associated with such QA. This applies to all levels of data, inclusion and exclusion criteria based on medical history, review of the radiotherapy and follow-up. While currently very time consuming, data QA stands to benefit a lot from integrated and automated systems. Computers will never replace a human when it comes to interpreting if a particular surgery constitutes a reason for making a patient ineligible for analysis. However, an application is required to stratify patients into passing QA and red-flagging those whose records have to be reviewed. Treatment databases with more complete records can be probed with routines designed to flag exclusion criteria, e.g., whether the patient was re-planned on a newly acquired CT during the course of therapy, whether all fractions were delivered, pre-existing conditions, chemotherapy regimens, etc.
A fully inclusive environment which connects patients' medical history, planning, and follow-up data would not only be a source of timely reporting outcomes for new technology, it would also serve as a monitor for undesirable outcomes or increased time patient spends in the room. This environment could facilitate continuous feedback for all practical aspects of radiotherapy delivery, zeroing in on factors that matter in a timely manner.
Both single-and multi-institution studies in outcomes and clinical effectiveness mimic the gold standard of medical investigations: a national clinical trial. Such efforts should not be seen as a replacement for the cooperative groups that facilitate these trials, but instead as enabling technologies that reduce the cost for investigators to answer clinical questions. Minimally, using these advances to conduct smaller scale investigations can be hypothesis generating, hinting at directions for future randomized clinical trials. It is possible that putting these tools into the hands of investigators will substantially lower the costs for operating clinical trials locally, allowing academic centers to pursue important clinical questions outside of the formal structure of cooperative group clinical trials.
7.E. Extra-institutional data sharing
The need for data-pooling culture for outcomes data analysis has been promoted for many years. 80, 81 Benefits of this are numerous, most obviously when it comes to decision support in treatment planning, i.e., what criteria should be used for judging the quality of a candidate treatment plan. For outcomes data analysis the obvious benefit is cross-validation of predictors of outcomes. Data pooling is also particularly valuable for low probability but highly adverse events, as what might be a once-in-a-decade event for an individual clinic should become more evident when looking across a larger population of clinical practices.
Logistically, data sharing is complex; data format, naming convention, and grading of toxicity are common problems. These problems, however, can be safely addressed using mediating software that reconcile differences or enforce conventions, as described in Sec. 5. Automated routines that impose standardization not only improve the possibility of extrainstitutional data analyses, but local efforts as well.
As previously noted, full disclosure of local outcomes may not be received enthusiastically by all parties, but informatics systems that lower the bar for the internal analysis of outcomes at least facilitates quantitative benchmarking and local quality improvement. Further, it would not take very many collaborating institutions to accumulate guidelines that are cross-validated. Interinstitutional sharing of outcomes data may be more widely accepted if clinics opt in to voluntary consortiums with established agreements as to how the data can be analyzed, queried, and publicized. Such consortiums can become sources of validated guidelines for treatment planning and use of modern technology as well as impact of this technology on outcomes.
HOW DO WE GET THERE?
To foresee these advancements might come to pass, it is useful to consider that most of the elements described in this paper have already been developed in some form by either academic radiotherapy centers 16, 21, 23, 24, 27, [82] [83] [84] or by commercial vendors targeting specific aspects of networked software delivery. The introduction of user-configurable Application Programming Interfaces (API) to clinical software systems is a particularly welcomed development, as it allows advanced clinical users to have more direct access to their own data and the tools built by these advanced users can provide demonstrations of how commercial software should evolve to better meet the needs of clinicians. Equally welcomed would be software vendors providing new gateways and toolkits for querying and analyzing the myriad data elements of clinical software systems, allowing institutions with less core programming expertise to conduct aggregate studies with less effort. With academic competition pushing for better aggregate clinical studies and vendor competition pushing for faster and better software implementations to meet this growing clinical need, we can expect that much of this vision is likely to be implemented in the coming years.
As academic investigations refine specific techniques and cloud-based installations become the expected vehicle for commercial software deployment, the groundwork will be laid for the applications described in Sec. 7. Perhaps the single most important thing that could accelerate this vision would be the widespread expectation from clinicians that next-generation computing must be part of clinical software.
When multipatient quality studies are seen as a "must have" function of oncology information systems and this demand begins to guide software purchasing agreements, the translation of existing academic informatics efforts into commercial systems becomes less a matter of if and more a matter of when.
The role of the clinical medical physicist in this process will be an indispensable one, both in foundational work and in implementation. While a clinical medical physicist's training does not currently include advanced programming, our key role in the quality assurance process ensures that we will be expected to manage the safe implementation of any practice-altering technologies. It is also likely that clinical physicists of all backgrounds and interests will be the primary users of these systems as they penetrate into clinical practice, and therefore have the most at stake as these technologies take shape. Given this, clinical medical physicists would benefit from becoming more knowledgeable consumers of IT services. Relevant topics in IT could be incorporated into continuing medical education programs. Integrating more explicit IT or programming components into medical physics residencies might also be warranted, especially since there are still a variety of possible educational backgrounds that qualify an individual for a CAMPEP-approved residency position.
The logistic demands of designing and implementing a fully cloud-based oncology information that allows clinicians to conduct automated longitudinal interinstitutional quality studies are, to say the least, quite formidable. Even if everything described in this paper were immediately available, it would take many years to convert the current fleet of clinical software installations to new systems. It is the authors' hope that the potential benefits are so compelling that clinicians and vendors alike can coalesce around a vision of how to fully realize the potentials of computers in radiation therapy.
CONCLUSIONS
In this Vision 20/20 paper we have forecast some of the elements of next-generation clinical informatics system. Like all forecasts, there are large uncertainties in the likelihood of particular predictions, though the integration of at least some of the ideas presented in this paper is nearly certain. Clinicians tasked to make use of next-generation systems can count on new tools that will allow them to better probe the myriad data generated in modern radiotherapy and can correspondingly expect that more will be asked of them in return. Clinical medical physicists are particularly well placed to guide the transition to these next-generation systems, as much of the implementation involves safe operation of these technologies, new procedure development, and maintaining quality assurance efforts even if computerized automation subsumes some or all of the routine QA in the clinic. a) Author to whom correspondence should be addressed. Electronic mail:
kevinmoore@ucsd.edu; Telephone: 858-822-6056.
